INTRODUCTION: RANKL, the receptor activator of nuclear factor kappa B ligand, is an essential factor for the formation of mature osteoclasts. Together with its receptor RANK and its antagonist Osteoprotegerin (OPG) RANKL is a key regulator in bone metabolism (1). RANKL is a membrane-bound protein that can be segregated to a soluble form (sRANKL), whereas only the latter has been reported to be bioactive (2). Due to its low circulating levels and the nature of the analyte binding to OPG, free sRANKL has been proven difficult to measure: the accuracy of sRANKL measurement is compromised by the very low or undetectable levels, as observed in some patient cohorts (3). Hence, our aim was to develop a highly sensitive and specific assay that enables the direct measurement of free, bioactive, soluble RANKL in serum and plasma samples.
METHODS:
The ELISA developed is based on a sandwich type format, whereas advantage of the high affinity and specificity proteinprotein interaction between sRANKL and OPG has been taken. Immobilized, recombinant OPG has been used to capture free sRANKL, which subsequently is detected with a biotin labeled anti-sRANKL antibody.
RESULTS:
The data presented here, demonstrate that all samples (n=127) from an unselected clinical and two apparently healthy populations had detectable free sRANKL values ( Fig. 2) within the calibration range of the assay (0 -2 pmol/, Fig. 1 ). The median of serum samples, prepared immediately after blood collection and stored at -25°C until measurement, was 0.14 pmol/l or 0.16 pmol/l respectively (Fig. 2 , healthy cohort I + II), with a lower limit of quantification (LLOQ) of 0.01 pmol/l. Assay characteristics, such as spike/recovery (Fig. 3) , dilution linearity (Fig. 4 ) and analyte stability in whole blood (Fig. 5 ) as well as intra/inter-assay precision (Fig. 6 
